A review on the clinical pharmacokinetics of hydralazine

References

• Herman LL, Bruss ZS, Tivakaran VS. Hydralazine. Treasure Island (FL):StatPearls Publishing;2021. eng.
   Google Scholar
• Reubi FC. Renal hyperemia induced in man by a new phthalazine derivative. Proc Soc Exp Biol Med. 1950;73(1):102–103.
   PubMed Web of Science ®Google Scholar
• Han LW, Ryu RJ, Cusumano M, et al. Effect of N‐acetyltransferase 2 genotype on the pharmacokinetics of hydralazine during pregnancy. J Clin Pharmacol. 2019;59(12):1678–1689.
   PubMed Web of Science ®Google Scholar
• McComb MN, Chao JY, Ng TM. Direct Vasodilators and Sympatholytic Agents. Journal of cardiovascular pharmacology and therapeutics. 2016 Jan;21(1):3–19.
   Google Scholar
• Kandler MR, Mah GT, Tejani AM, et al. Hydralazine for essential hypertension. In: Cochrane database of systematic reviews. 2011;11. DOI:10.1002/14651858.CD004934.pub4
   Google Scholar
• Herting RL, Hunter HL. The physiologic and pharmacologic basis for the clinical treatment of hypertension. Med Clin North Am. 1967;51(1):25–37.
   PubMed Web of Science ®Google Scholar
• Kirsten R, Nelson K, Kirsten D, et al. Clinical pharmacokinetics of vasodilators Part I. Clin pharmacokinet. 1998 Jun;34(6):457–482
   PubMed Web of Science ®Google Scholar
• Papich MG, Martinez MN. Applying biopharmaceutical classification system (BCS) criteria to predict oral absorption of drugs in dogs: challenges and pitfalls. AAPS J. 2015;17(4):948–964.
   PubMed Web of Science ®Google Scholar
• von Mollendorff E, Reiff K, Neugebauer G. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clin Pharmacol. 1987;33(5):511–513.
   PubMed Web of Science ®Google Scholar
• Reidenberg MM, Drayer D, DeMarco AL, et al. Hydralazine elimination in man. Clin Pharmacol Ther. 1973;14(6):970–977
   PubMed Web of Science ®Google Scholar
• St Peter W, Halstenson C. Pharmacologic approach in patients with renal failure. Pharmacol Approach Critically Ill Patient Williams and Wilkins, Baltimore. 1994: 41–80
   Google Scholar
• Talseth T. Clinical pharmacokinetics of hydralazine. Clin Pharmacokinet. 1977;2(5):317–329.
   PubMedGoogle Scholar
• Ludden T, Shepherd A, McNay J, et al. Hydralazine kinetics in hypertensive patients after intravenous administration. Clin Pharmacol Ther. 1980;28(6):736–742.
   PubMed Web of Science ®Google Scholar
• Reece PA, Cozamanis I, Zacest R. Selective high-performance liquid chromatographic assays for hydralazine and its metabolites in plasma of man. J Chromatogr B. 1980;181(3–4):427–440.
   Google Scholar
• Talseth T. Studies on hydralazine. Eur J Clin Pharmacol. 1976;10(6):395–401.
   PubMed Web of Science ®Google Scholar
• Hanson A, Johansson B, Wernersson B, et al. Pharmacokinetics of oral hydralazine in chronic heart failure. Eur J Clin Pharmacol. 1983;25(4):467–473.
   PubMed Web of Science ®Google Scholar
• Talseth T. Studies on hydralazine. I. serum concentrations of hydralazine in man after a single dose and at steady-State. 1976.
   Google Scholar
• Reece PA, Cozamanis I, Zacest R. Kinetics of hydralazine and its main metabolites in slow and fast acetylators. Clin Pharmacol Ther. 1980;28(6):769–778.
   PubMed Web of Science ®Google Scholar
• Wormhoudt LW, Commandeur JN, Vermeulen NP. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol. 1999;29(1):59–124.
   PubMed Web of Science ®Google Scholar
• Antza C, Doundoulakis I, Akrivos E, et al. Hydralazine in pregnancy: a systematic review and meta-analysis. J Hypertens. 2019;37:e40.
   Web of Science ®Google Scholar
• Gaynor MF, Wright GC, Vondracek S. Retrospective review of the use of as-needed hydralazine and labetalol for the treatment of acute hypertension in hospitalized medicine patients. Ther Adv Cardiovasc Dis. 2018;12(1):7–15.
   PubMedGoogle Scholar
• Baek IH, Yun MH, Yun HY, et al. Pharmacokinetic/pharmacodynamic modeling of the cardiovascular effects of beta blockers in humans. Arch Pharm Res. 2008 Jun;31(6):814–821.
   PubMed Web of Science ®Google Scholar
• Clark HD, Wells GA, Huët C, et al. Assessing the quality of randomized trials: reliability of the Jadad scale. Controlled Clin Trials. 1999;20(5):448–452.
   PubMedGoogle Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. In: Bmj. 2011;343. DOI: 10.1136/bmj.d5928.
   Google Scholar
• Shen DD, Hosler JP, Schroder RL, et al. Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype. J Pharmacokinet Biopharm. 1980;8(1):53–68.
   PubMedGoogle Scholar
• Garcés‐Eisele S, Cedillo‐Carvallo B, Reyes‐Núñez V, et al. Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. J Clin Pharm Ther. 2014;39(4):368–375.
   PubMed Web of Science ®Google Scholar
• Talseth T. Kinetics of hydralazine elimination. Clin Pharmacol Ther. 1977;21(6):715–720.
   PubMed Web of Science ®Google Scholar
• Ludden T, Ludden L, McNay J, et al. Improved assays for hydralazine and hydralazine pyruvic acid hydrazone in human plasma. Anal Chim Acta. 1980;120:297–304.
   Web of Science ®Google Scholar
• McLean A, Wilhelm D, Heinzow B. Stable oral availability of atenolol coadministered with hydralazine. Drugs. 1983;25(2):131–135.
   Google Scholar
• McLean AJ, Skews H, Bobik A, et al., Interaction between oral propranolol and hydralazine. Clin Pharmacol Ther. 1980;27(6): 726–732.
   PubMed Web of Science ®Google Scholar
• Jack DB, Kendall MJ, Dean S, et al. The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: metoprolol, nadolol, and acebutolol. Biopharm Drug Dispos. 1982;3(1):47–54.
   PubMed Web of Science ®Google Scholar
• Lindeberg S, Holm B, Lundborg P, et al. The effect of hydralazine on steady-state plasma concentrations of metoprolol in pregnant hypertensive women. Eur J Clin Pharmacol. 1988;35(2):131–135.
   PubMed Web of Science ®Google Scholar
• Melander A, Danielson K, Hanson A, et al. Enhancement of hydralazine bioavailability by food. Clin Pharmacol Ther. 1977;22(1):104–107.
   PubMed Web of Science ®Google Scholar
• Walden R, Hernandez R, Witts D, et al., Effect of food on the absorption of hydralazine in man. Eur J Clin Pharmacol. 1981;20(1): 53–58.
   PubMed Web of Science ®Google Scholar
• Shepherd AM, Irvine NA, Ludden TM. Effect of food on blood hydralazine levels and response in hypertension. Clin Pharmacol Ther. 1984;36(1):14–18.
   PubMed Web of Science ®Google Scholar
• Jackson SH, Shepherd AM, Ludden TM, et al. Effect of food on oral availability of apresoline and controlled release hydralazine in hypertensive patients. J Cardiovasc Pharmacol. 1990 Oct;16(4):624–628.
   PubMed Web of Science ®Google Scholar
• Sabir S, Yasmin S, Abbas G. Comparison of oral nifedipine with intravenous hydralazine for acute hypertensive emergencies of pregnancy. J Postgrad Med Inst. 2016;30:4.
   Google Scholar
• Sharma C, Soni A, Gupta A, et al. Hydralazine vs nifedipine for acute hypertensive emergency in pregnancy: a randomized controlled trial. Am J Obstet Gynecol. 2017;217(6):e1–687. e6
   PubMed Web of Science ®Google Scholar
• De Pasquale SD, Velarde R, Reyes O, et al. Hydralazine vs labetalol for the treatment of severe hypertensive disorders of pregnancy A randomized, controlled trial. Pregnancy Hypertens: Int J Women’s Cardiovasc Health. 2014;4(1):19–22.
   Web of Science ®Google Scholar
• Kalam MN, Rasool MF, Rehman AU, et al. Clinical pharmacokinetics of propranolol hydrochloride: a review. Curr Drug Metab. 2020;21(2):89–105.
   PubMed Web of Science ®Google Scholar
• Johnson TN, Boussery K, Rowland-Yeo K, et al. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010;49(3):189–206.
   PubMed Web of Science ®Google Scholar